ライフサイエンスコーパス: age-related

1 The age-related acquisition of somatic mutations that lead t

2 al stem/progenitor cells (ANSPCs), underlies age-related alterations in adult hippocampal neurogenesi

3 These findings demonstrate that age-related alterations in neutrophils and eosinophils a

4 We therefore propose that LDAM contribute to age-related and genetic forms of neurodegeneration.

5 Hepatocellular carcinoma (HCC) is clearly age-related and represents one of the deadliest cancer t

6 nflammation before hyperlipidemia may reduce age-related atherosclerosis.

7 adults are living to the stage of life when age-related biological factors determine a higher likeli

8 Age-related CA1 DEGs, correlated with spatial memory, we

9 IFICANCE STATEMENT Prior work suggested that age-related CA3 hyperactivity enhances pattern completio

10 It is not known whether age-related CA3 hyperactivity is uniformly represented a

11 The need for interventions to combat this age-related cardiac decline is becoming increasingly urg

12 xcessive proton leak as a novel mechanism of age-related cardiac dysfunction and elucidate how SS-31

13 ntribute to the non-autonomous regulation of age-related cardiac dysfunction.

14 CICUs), where care is commensurate with high age-related cardiovascular disease risks but where the a

15 lation: Forty-three eyes of 43 patients with age-related cataract and CA(tot) between 1 and 3 diopter

16 A total of 381 eyes of 199 patients with age-related cataract received an IOL Acrysof SN60WF, Tec

17 but there was no evidence of early onset of age-related cataracts in DS.

18 ) in the DS group had clinically significant age-related cataracts, but there was no evidence of earl

19 and Sweden were reviewed to select eyes with aged-related cataracts, having undergone crystalline len

20 Aging-related cellular and molecular processes including

21 Twin studies show that age-related change in symptoms of attention-deficit/hype

22 as their aortas and kidneys revealed typical age-related changes (arteriosclerosis and glomeruloscler

23 mpared with young wild-type mice and greater age-related changes at 12 to 13 months of age.

24 Age-related changes in bone microstructure and strength

25 dress this question, herein we characterized age-related changes in both the transcriptome and transl

26 Here, we investigated the age-related changes in epidermal Langerhans cells (LCs),

27 lls (HSCs) are thought to be responsible for age-related changes in haematopoiesis that include a dec

28 lammaging") has been proposed as a driver of age-related changes in HSC function and myeloid malignan

29 nding proteins, and to determine gestational age-related changes in maternal and fetal plasma FA conc

30 Age-related changes in MCT, CVV, CSV, and CVI were studi

31 Microarray analysis revealed age-related changes in multiple genes, including some wi

32 In humans, age-related changes in personality occur in a non-random

33 is review, we summarize published results on age-related changes in response to infection with the in

34 Five sets of studies examined age-related changes in the AONpP.

35 A final study found no age-related changes in the density of vasculature in the

36 However, the age-related changes in the immune function of human skin

37 ncreased near stop codons, revealing complex age-related changes in the translation process.

38 We demonstrate statistically significant age-related changes in triglycerides (TG), diglycerides

39 Here, we examine age-related changes in urinary cortisol in a 20-y longit

40 Moreover, marked age-related changes occurred in many nonepithelial cell

41 Currently, we know very little about age-related changes occurring in the auditory sensory ce

42 of CRYalphaA(N101D)- vs. CRYalphaA(WT) mice: age-related changes with specific emphasis on protein in

43 stic of aging human brain, and may influence aging-related changes in brain functions.

44 CR attenuated aging-related changes in cell type composition, gene exp

45 ed single-cell RNA-sequencing to interrogate aging-related changes in the HFSCs.

46 We validated AGE-related codes in pediatric and adult populations usi

47 stage biomarkers in those at risk for AD and age-related cognitive decline (ARCD) in order to develop

48 associated with reduced hippocampal volumes, age-related cognitive decline and psychiatric disorder r

49 romising intervention strategy for combating age-related cognitive decline in otherwise healthy indiv

50 Faster rates of age-related cognitive decline might result in early onse

51 No approved treatments exist for age-related cognitive decline.

52 ive training for adults age 65 or older with age-related cognitive decline.

53 Age-related cognitive impairments are associated with di

54 ion as a potential mechanism contributing to age-related cognitive impairments.SIGNIFICANCE STATEMENT

55 The results indicated that age-related common EF component differences are mediated

56 for dry AMD patients who have another common age-related comorbidity, senile systemic amyloidosis, a

57 at may be compromised in cognitive aging and age-related conditions such as mild cognitive impairment

58 nd promising therapeutic target for multiple age-related conditions, ranging from neurodegeneration t

59 op new therapeutic strategies for a range of age-related conditions.

60 e explore the synaptic function of A(2A)R in age-related conditions.

61 d qAF levels >95% prediction interval of the age-related control group, with best discrimination betw

62 Age-related decay can eventually lead to pathology such

63 Thus, age-related decline in neuronal health or expression of

64 The normal age-related decline in proportions of submucosal dopamin

65 centricities and a significant difference in age-related decline of CVI with eccentricity only occurr

66 t start to establish molecular mechanisms of age-related decline of mammalian ISC function.

67 Age-related decline of neurogenesis is paralleled by a p

68 eveals variability and a normal mean rate of age-related decline, consistent with largely nonprogress

69 ans, dolphins exhibit independent and linear age-related declines in four of these measures: hemoglob

70 It leads to age-related declines in reproduction (reproductive senes

71 eritable diseases, acquired pathologies, and aging-related declines in health.

72 whole-brain correlation analysis revealed an age-related decrease in language activation only in the

73 Interestingly, the age-related decrease in type 3 mediators was associated

74 Age-related decreases in transcript/protein expression w

75 lial cells of the Drosophila retina leads to age-related degeneration of both glia and neurons, prece

76 cumulation in the RPE cells during aging and age-related degeneration.

77 hology is a likely pathogenic contributor to age-related dementia, including Alzheimer's disease, ine

78 xhibit similar neural responding to threats, age-related differences have been found in some function

79 ge 9-14 years, whereas controls displayed no age-related differences in diversity.

80 d functional network properties that mediate age-related differences in EF components remain unclear.

81 lt) RSV-infected C57BL/6 mice to investigate age-related differences in immunologic responses; juveni

82 investigated the functional significance of age-related differences in mean normalized LC signal int

83 ultivariable statistical models demonstrated age-related differences in seroprevalence, with signific

84 These findings suggest that the FPN mediates age-related differences in specific components of EF.

85 We studied whether age-related differences in the noradrenergic system pred

86 use-adapted SARS-CoV-2 MA model demonstrates age-related disease pathogenesis and supports the clinic

87 Short telomere length is a risk factor for age-related disease, but it is also associated with redu

88 hrough which adversity may increase risk for age-related disease.

89 nes that are not known to be associated with age-related diseases according to our dataset.

90 a high probability of being associated with age-related diseases according to the model.

91 st robust means to extend lifespan and delay age-related diseases across species.

92 compiled list of human genes associated with age-related diseases and apply a novel Deep Neural Netwo

93 ospholipids that may serve as biomarkers for age-related diseases and could potentially be used as ta

94 e the potential to prevent and treat various age-related diseases and extend healthspan.

95 ing the pathways linking these exposures and age-related diseases but need further confirmation in th

96 ered a cause of and a therapeutic target for age-related diseases including neurodegenerative disorde

97 ing of the molecular regulation of aging and age-related diseases is still in its infancy, requiring

98 hat the connection between gut dysbiosis and age-related diseases may lie in how the gut microbiome c

99 shape could hold prognostic information for age-related diseases that affect lung tissue mechanics.

100 roxidation) is linked with oxidative stress, age-related diseases, and cancers.

101 diseases, taken as a paradigmatic example of age-related diseases, as well as other emerging topics i

102 In humans, various genetic defects or age-related diseases, such as diabetic retinopathies, gl

103 lti-trait loci have been linked with several age-related diseases, suggesting shared ageing influence

104 ess dysbiotic microbiome to prevent or treat age-related diseases.

105 s, with a promising therapeutic potential in age-related diseases.

106 ysfunctions are a common feature of multiple age-related diseases.

107 xic effects that are associated with several age-related diseases.

108 discuss their implications in senescence and age-related diseases.

109 data and biological pathway information) and age-related diseases.

110 rs in the context of senescence, ageing, and age-related diseases.

111 netic contributors to cancers and many other age-related diseases.

112 he capability to avoid or postpone the major age-related diseases; and 2) a high level of heterogenei

113 n, delay, and/or alleviation of a variety of aging-related diseases and sequelae.

114 ted with an increased risk of brain atrophy, aging-related diseases, and mortality.

115 (PD) is a devastating, largely nonfamilial, age-related disorder caused by the progressive loss of d

116 It is a genetically complex and age-related disorder, with higher incidence in females.

117 ysfunction have been demonstrated in several age-related disorders including osteoarthritis, yet its

118 ovel therapeutic approaches to metabolic and age-related disorders such as osteoporosis and diabetes

119 ar senescence, which contributes to advanced age-related disorders, it is unclear how Kruppel-like fa

120 eration, Alzheimer's disease, and many other age-related disorders.

121 s for progress in molecular understanding of aging-related disorders and neurodegenerative diseases.

122 ociated with increased life span and reduced aging-related disorders and reduces fibrosis in several

123 low-level spontaneous DNA damage, including age-related DNA lesions, DNA breaks induced by several a

124 e of Parkinson's disease (PD) and results in age-related dopamine neuron loss and locomotor dysfuncti

125 ble therapeutic approach in the treatment of age-related dry eye disease.

126 w-grade inflammation and oxidative stress in age-related dry eye.

127 Age-related epigenomic changes first spike around late-t

128 increased CpG density is protective against age-related erosion of the epigenetic landscape and may

129 Age-related eye disease may be associated with cognitive

130 Alzheimer's disease (AD) is the most common age-related form of dementia, associated with deposition

131 ontal lobe may have an indirect influence on age-related general elements of EF.

132 ) and animals subjected to RNAi knockdown of age-related genes (age-1 and daf-16).

133 rtance for the development of treatments for age-related hearing disorders.

134 Age-related hearing loss (ARHL) is a common problem for

135 Age-related hearing loss (ARHL) is a very heterogeneous

136 ty risk factors and studied multiplex family age-related hearing loss (mARHL) and simplex/sporadic ag

137 ed hearing loss (mARHL) and simplex/sporadic age-related hearing loss (sARHL) cases and controls with

138 Age-related hearing loss is a progressive hearing loss i

139 People suffering from age-related hearing loss typically present with deficits

140 system could be a viable strategy to prevent age-related hearing loss.

141 nal changes in IHCs are a potential cause of age-related hearing loss.

142 ion/treatment of inner ear disorders such as age-related hearing loss.

143 s directly contributes to the progression of age-related hearing loss.

144 dings concerning the molecular mechanisms of age-related heart failure and highlight exercise as a va

145 Age-related heart impairment is lacking a clinically eff

146 mics and functional significance of putative aging-related heterogeneity are also unknown.

147 arkers and potential therapeutic targets for age-related human ovarian disorders.

148 re preserved in healthy ageing, and thus the age-related impairment in functional sympatholysis proba

149 within BMECs that potentially underlies the age-related impairment of their niche activity.

150 showed that a few individuals with potential age-related impairments significantly affected the gener

151 executive performance and partially mediated age-related improvements in executive function.

152 for and against hippocampal contributions to age-related improvements in memory performance, but has

153 s, or older age because of the physiological age-related increase in qAF and a ceiling effect in pati

154 CRSsNP and NENP showed an age-related increase in type 2 cytokines and a decline i

155 ENP showed an age-related increase in type 3 cytokines with type 2 med

156 Age-related increases in CD36 mRNA expression were obser

157 We find age-related increases in the distinctiveness of temporal

158 Our data suggest that age-related increases in the memory Th17 compartment pre

159 nuclear and cytosolic sirtuin inhibition to aging-related inflammatory disease development.

160 rget of cellular stress, toxin exposure, and aging-related injury.

161 ent firing capacity, which may contribute to aging-related learning impairments.

162 An age-related loss of cholinergic neuromodulation may remo

163 It has been suggested that an age-related loss of cognitive function might be driven b

164 ordance with histopathologic studies showing age-related loss of retinal ganglion cell axons, we show

165 Here we report that age-related loss of the posttranslational modification,

166 initiate testosterone treatment in men with age-related low testosterone to improve energy, vitality

167 initiate testosterone treatment in men with age-related low testosterone with sexual dysfunction who

168 tment to improve sexual function in men with age-related low testosterone, as costs are considerably

169 of testosterone treatment in adult men with age-related low testosterone.

170 t patient population includes adult men with age-related low testosterone.

171 in direct or indirect costs associated with age-related macular degeneration ($17 379.41-$657 406.55

172 nts were 55 to 90 years with GA secondary to age-related macular degeneration (AMD) and best-correcte

173 HTRA1) are associated with increased risk of age-related macular degeneration (AMD) and disease progr

174 f depression and anxiety among subjects with age-related macular degeneration (AMD) and its associati

175 ator, are associated with the development of age-related macular degeneration (AMD) and other complem

176 Current prediction models for advanced age-related macular degeneration (AMD) are based on a re

177 en was tested in eyes with large drusen from age-related macular degeneration (AMD) before and after

178 the RNFL thinning may be secondary to active age-related macular degeneration (AMD) disease progressi

179 Offspring of parent(s) with age-related macular degeneration (AMD) have a 45% lifeti

180 Age-related macular degeneration (AMD) is a chronic eye

181 rowth factor (VEGF) treatment of neovascular age-related macular degeneration (AMD) is a highly effec

182 Age-related macular degeneration (AMD) is the leading ca

183 phagocytes are implicated in the etiology of age-related macular degeneration (AMD), a major cause of

184 ht-threatening ocular comorbidity other than age-related macular degeneration (AMD), diabetic retinop

185 e choroid contributes to the pathogenesis of age-related macular degeneration (AMD), the role of reti

186 st arose at 80 years of age or later, showed age-related macular degeneration (AMD)-like fundus chang

187 l study visits and graded centrally for late age-related macular degeneration (AMD).

188 be one of the first cell classes affected by age-related macular degeneration (AMD).

189 t geographic atrophy (GA) onset secondary to age-related macular degeneration (AMD).

190 nd at a younger age than in individuals with age-related macular degeneration (AMD).

191 rce-optical coherence tomography (SS-OCT) in age-related macular degeneration (AMD).

192 ical studies link Periodontal disease(PD) to age-related macular degeneration (AMD).

193 eat colorectal and breast cancers as well as age-related macular degeneration (AMD).

194 hat prevent or delay development to advanced age-related macular degeneration (AMD).

195 Progression to exudative 'wet' age-related macular degeneration (exAMD) is a major caus

196 acuity (VA) change in real-world neovascular age-related macular degeneration (nAMD) patients.

197 cular occlusion in patients with neovascular age-related macular degeneration (nAMD) treated with int

198 visual outcomes in patients with neovascular age-related macular degeneration (nAMD) who received ant

199 olucizumab versus aflibercept in neovascular age-related macular degeneration (nAMD).

200 .5 mg for eligible patients with neovascular age-related macular degeneration (nAMD).

201 e main goal for the treatment of neovascular age-related macular degeneration (nAMD).

202 Francisco, CA) in patients with neovascular age-related macular degeneration (nAMD).

203 nd aflibercept monotherapies for neovascular age-related macular degeneration (NVAMD).

204 R, retinopathy of prematurity (ROP), and wet age-related macular degeneration (wet AMD) have been fou

205 Roclatan for glaucoma, Brolucizumab for wet age-related macular degeneration (wet AMD), Luxturna for

206 se taking metformin were less likely to have age-related macular degeneration compared with those not

207 , active choroidal neovascularization due to age-related macular degeneration in the study eye were r

208 Age-related macular degeneration is a leading cause of v

209 Age-related macular degeneration is a major cause of vis

210 Geographic atrophy (GA) secondary to age-related macular degeneration is considered a single

211 phic atrophy (GA), a progressive dry form of age-related macular degeneration is elusive and there is

212 treal aflibercept injections for neovascular age-related macular degeneration presented 4 weeks after

213 me and generic multivitamin formulations for age-related macular degeneration were obtained.

214 ncluding atrophy outcome(s) in patients with age-related macular degeneration who received anti-VEGF

215 year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in th

216 ent of the abnormal deposits associated with age-related macular degeneration, Alzheimer's disease, a

217 lar pathologic features, including glaucoma, age-related macular degeneration, and epiretinal membran

218 , after adjusting for age, gender, glaucoma, age-related macular degeneration, diabetic retinopathy,

219 In age-related macular degeneration, the retinal pigment ep

220 l diseases including an epiretinal membrane, age-related macular degeneration, vitreomacular traction

221 phy (OCT) volume scans of 1094 patients with age-related macular degeneration, we generated a vocabul

222 ) mainly focused on diabetic retinopathy and age-related macular degeneration.

223 for therapeutics and diagnostics directed at age-related macular degeneration.

224 sthesis in patients affected by dry atrophic age-related macular degeneration.

225 typical hemolytic uremic syndrome (aHUS) and age-related macular degeneration.

226 tings of inherited retinal degenerations and age-related macular degeneration.Literature discussed he

227 color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.

228 stics of drusen and other lesions typical of age-related maculopathy were determined by grading stere

229 Age-related mechanisms may provide novel therapeutic tar

230 Age-related memory deficits are correlated with neural h

231 t provides new insight in the role of CA3 in age-related memory impairments, suggesting that the rigi

232 ENT A high percentage of subjects experience age-related memory loss that burdens daily performance.

233 lity in older populations regarding numerous age-related metrics like time-to-death, time-to-coronary

234 Dosmit offers a promising target for future age-related mitochondrial disease therapies.

235 Age-related mitochondrial dysfunction and associated oxi

236 Although the age-related morphological changes at IHC ribbon synapses

237 ngs from L5B pyramidal output neurons showed age-related nAChR subunit-selective reductions in postsy

238 ligand-CCR2 signaling in the development of age-related NAFLD.

239 the intrathecal space of brains affected by age-related neurodegeneration.

240 strongly associated with an elevated risk of age-related neurodegenerative diseases including Alzheim

241 ms intranuclear or cytoplasmic aggregates in age-related neurodegenerative diseases.

242 This is relevant in aging and age-related neurological diseases, where neuroinflammati

243 has increased the number of individuals with age-related neurological movement disorders including Pa

244 cohort overall were consistently lower than age-related norms.

245 ysregulated energy metabolism driving toward age-related obesity.

246 Aging-related organ degeneration is driven by multiple f

247 Age-related osteoporosis is characterized by the deterio

248 lphaKG in rejuvenating MSCs and ameliorating age-related osteoporosis, with a promising therapeutic p

249 a common feature of various neurological and age-related pathologies, making this pathway an attracti

250 These age-related patterns in each CRS were confirmed by stati

251 traits were related to longevity, suggesting age-related patterns were not the result of selective di

252 our knowledge about the detailed dynamics of age-related personality changes.

253 tissue homeostasis, accelerate the onset of age-related phenotypes, and increase the risk for skin c

254 ew the links between these novel factors and age-related phenotypes, and we suggest tools that can be

255 ) age prediction are correlated with several age-related phenotypes, such as mortality and frailty.

256 unit cell type vulnerable to its own set of age-related phenotypes, the effects of ageing might in f

257 Little is known about the age-related physiological and morphological changes that

258 lity-related processes rather than normative age-related processes.

259 eneration by altering the homeostasis of key aging-related processes.

260 aA(N101D) mice exhibited: (A) An increase in age-related protein insolubilization beginning at about

261 e a therapeutic target for the prevention of age-related reduction in LCs.

262 Despite the age-related reduction in ribbon number in three of the f

263 ncy arteriolar oscillations and suggest that age-related reduction of this vasomotion may contribute

264 oteasome inhibition within neurons, to mimic aging-related reduction of proteasome activity, induced

265 l (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampu

266 This review presents a model for age-related regenerative decline in the fly intestine an

267 ched fractions were used to characterize the age-related senescence-associated secretory phenotype (S

268 Older listeners with age-related sensorineural hearing loss (presbycusis) oft

269 selection.SIGNIFICANCE STATEMENT People with age-related sensorineural hearing loss often struggle to

270 e clinical presentation at onset, showing an age-related shift in the clinical features across age gr

271 s are lacking for sarcopenia, a debilitating age-related skeletal muscle wasting syndrome.

272 nd studying the mechanisms of skin aging and age-related skin disorders.

273 tic evidence that ADORA2B is detrimental for age-related SNHL by impairing cochlear myelination in WT

274 nscript/protein expression were reflected in age-related subunit specific functional loss of nAChR si

275 later in time (~3 years) in cases of primary age-related tauopathy compared to Alzheimer's disease.

276 dence to support the hypothesis that primary age-related tauopathy has distinct neuropathological and

277 borate previous studies showing that primary age-related tauopathy has slower cognitive decline than

278 and either no neuritic plaques (i.e. primary age-related tauopathy) or moderate to frequent neuritic

279 gies, including Alzheimer's disease, primary age-related tauopathy, ageing-related tau astrogliopathy

280 atients with Alzheimer's disease and primary age-related tauopathy, we compared rates of decline in t

281 l atrophy in Alzheimer's disease and primary age-related tauopathy, whether either protein is also as

282 of the neuropsychological burden in primary age-related tauopathy.

283 l atrophy in Alzheimer's disease and primary age-related tauopathy.

284 sistent with Alzheimer's disease and primary age-related tauopathy.

285 VRs were not elevated in Braak IV or primary age-related tauopathy.

286 ed TDP-43 proteinopathy: limbic-predominant, age-related TDP-43 encephalopathy (LATE) and the underly

287 minology was recommended recently for common age-related TDP-43 proteinopathy: limbic-predominant, ag

288 This suggests that age-related temporal processing deficits may develop mor

289 activity decline, which suggests that these age-related traits can be regulated through distinct mec

290 The age-related trajectory of motor unit discharge character

291 We took advantage of age-related variability in performance on a water maze b

292 Here, we examine age-related variation in body mass, reproductive output

293 However, age-related vascular changes accompany or even precede t

294 provide a proof of concept for understanding age-related vascular changes and imply that therapeutic

295 s provide a potential therapeutic target for age-related vascular disorders.

296 sent study establish the temporal pattern of age-related vascular dysfunction across the adult lifesp

297 Aging-related vascular and cardiac deposition of Alphabe

298 imal test protocol to explore the changes in age-related VO(2max).

299 gical stress by increasing the occurrence of age-related vulval integrity disorder.

300 ion MRI data to comprehensively characterize age-related white matter trajectories, as measured by fr